US00972G2075 - ADR
4.05 +0.2 (+5.19%)
AKARI THERAPEUTICS PLC-ADR
NASDAQ:AKTX (9/26/2023, 7:00:00 PM)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Akari Therapeutics PLC is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 15 full-time employees. The company went IPO on 2014-01-31. Akari Therapeutics, Plc is a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. The firm's lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The firm has been granted Orphan Drug, Fast Track and Rare Pediatric Disease designations from the United States Food and Drug Administration (FDA) for nomacopan for the treatment of pediatric HSCT-TMA. Additionally, the Company has a pre-clinical program developing long-acting PASylated-nomacopan (PAS-nomacopan) for treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD).
AKARI THERAPEUTICS PLC-ADR
22 BOSTON WHARF ROAD, FL 7
Boston MASSACHUSETTS W1G 9RT
CEO: Clive Richardson
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Event on October 19, 2023 will feature Sonata Jodele, MD and Professor Rob Wynn BOSTON and LONDON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Akari...
NEW YORK and LONDON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced...
NEW YORK and LONDON, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced...
It's time for another dive into the biggest pre-market stock movers this morning as we check out the latest news on Thursday!
Akari Therapeutics (AKTX) said on Tuesday that it plans to change the ratio of its American Depositary Shares to ordinary shares from one ADS representing one hundred ordinary shares to...
Here you can normally see the latest stock twits on AKTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.